SYNTHESIS, ANTI-PROLIFERATIVE ACTIVITY AND 2D-QSAR STUDY OF SOME 8-ALKYL-2,4-BISBENZYLIDENE-3-NORTROPINONES

<u>Riham F. George^a</u>, Nermin Samir^b, Iriny M. Ayoub^c, ElSayed M. Shalaby^{d,e}, Nicola Demitri^e, Michael Wink^f

 ^a Pharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt
^b Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, African Union Organization Street, Cairo 11566, Egypt
^c Department of Pharmacognosy, Faculty of Pharmacy, Ain Shams University, African Union Organization Street, Cairo 11566, Egypt
^d X-Ray Crystallography Lab., Physics Division, National Research Centre, Dokki, Giza 12622, Egypt
^eElettra-Sincrotrone Trieste S.C.p.A., AREA Science Park, 34149 Basovizza, Trieste, Italy
^f Institute of Pharmacy and Molecular Biotechnology, INF 364, Heidelberg University, D-69120 Heidelberg, Germany

Colon cancer is the third leading cause of death worldwide; therefore, there is a need for an effective therapy with lower side effects. A series of 8-alkyl-2,4-bisbenzylidene-3nortropinones **10-36** was prepared via Claisen-Schmidt condensation of 8-alkyl-3nortropinones **7-9** with different aromatic aldehydes. The target compounds were screened for their anti-proliferative activity. Most of the prepared compounds showed promising anti-proliferative activity against many of 60 NCI cell lines at 10 μ M. Furthermore, 8-ethyl-2,4-bis(3,4-dimethoxybenzylidene)-8-nortropin-3-one **26** and its 3,4,5-trimethoxy analog **27** were the most active compounds against HCT116 cell line with IC₅₀ values 0.01 and 0.46 μ M, respectively. Using CODESSA-Pro software, a significant 2D-QSAR model was obtained. Therefore, 8-alkyl-2,4-bisbenzylidene-8azabicyclo[3.2.1]octan-3-one represents an interesting core for further structural optimization to obtain more promising hits.



Schematic pathway for preparation of 8-alkyl-2,4-bisbenzylidene-3-nortropinones 10-36



ORTEP projection of single crystal X-ray diffraction of compound 23